Moteur de recherche d’entreprises européennes
Financement de l’UE (3 345 728 €) : Réseau doctoral européen pour la relecture du protéome Hor 04/07/2026 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
Réseau doctoral européen pour la relecture du protéome
Targeted Protein Degradation (TPD), an innovative strategy to redirect the cellular degradation machinery towards the elimination of disease-relevant proteins, has attracted enormous attention from researchers, industry and clinicians. TPD is based on the capacity of a small molecule, the degrader, to re-route the ubiquitination machinery towards a selected protein of interest to trigger its ubiquitination and degradation by the Ubiquitin Proteasomal System, via its interaction with specific E3 ubiquitin ligases. ProofReading will bring together a diverse community, assembling the necessary multidisciplinary expertise to develop novel TPD approaches applicable to various cellular and disease contexts, facilitating the generation of degraders. ProofReading will establish an interdisciplinary, intersectoral and international research programme to drive the development of tools, degraders and innovative strategies aimed at eliminating targets involved in cancer, infection, inflammation and rare diseases. The network comprises 10 universities, 4 research centres and 8 innovative companies, which will provide state-of-the-art training for the recruited Doctoral Candidates (DCs). This is the only doctoral network related to proteome proofreading by using TPD that combines the knowledge in all disciplines, ranging from life to physical sciences, required to develop a degrader. Interdisciplinary and intersectoral secondments will expose the DCs to different working environments. We will organize 5 hands-on research workshops on central methodological and technical aspects of TPD and 7 courses on transferable skills, of primary importance for increasing the employability of the DCs. We will also address the important issue of mental health and well-being in science. ProofReading will train 11 researchers with specific knowledge in the cutting-edge technology of TPD, which will contribute to the generation of future drugs to treat diseases.
| Atlas Molecular Pharma SL | ? |
| Asociacion Centro de Investigacion CRL en Biociencias | 564 376 € |
| Astrazeneca UK Ltd. | 348 738 € |
| Centre National de la Recherche Scientifique CNRS | 314 669 € |
| Dynamic Biosensors GmbH | 290 272 € |
| Ecole Polytechnique Federale DE Lausanne | 380 642 € |
| Forschungsinstitut FUR Molekulare Pathologie GmbH | 302 543 € |
| Johann Wolfgang Goethe-Universitaet Frankfurt AM Main | 290 272 € |
| Philipps Universitaet Marburg | 290 272 € |
| Universita Degli Studi Di Milano | 281 755 € |
| Universitat de Barcelona | 282 188 € |
https://cordis.europa.eu/project/id/101311289
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel. L’état actuel est présenté à la page suivante : Atlas Molecular Pharma SL, Derio, Espagne.